GLOBALHealthPR

First-Ever Therapy to Demonstrate Survival Benefit in Progeria

A new study published in The Journal of the American Medical Association (JAMA) reports that lonafarnib, a farnesyltransferase inhibitor (FTI), helped extend survival in children with Hutchinson-Gilford Progeria Syndrome (HGPS), or Progeria, an ultra-rare and fatal disease that causes premature aging in children. Children with Progeria live an average 14 ½ years, dying from heart…

Read More

South Africa’s leading independent health communications agency joins GLOBALHealthPR

World’s largest independent healthcare communications network strengthens market-leading offering across Asia Pacific, North America, South America, Europe & Africa GLOBALHealthPR®, the largest independent health and science communications agency partnership worldwide, represented exclusively by VIVA! Communications in Australia, today welcomed Johannesburg-based F/NE to its rapidly expanding global network. Founded more than 18 years ago, F/NE has…

Read More